A retrospective study for association between post-transfusion hemoglobin S level and pre-transfusion hemoglobin S level at the next scheduled transfusion.
follow up HbS
post-HCT
post-HbS
red cell exchange
sickle cell disease
transfusion
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
12
03
2023
received:
08
08
2022
accepted:
30
04
2023
pubmed:
18
5
2023
medline:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Patients with sickle cell disease (SCD) frequently undergo prophylactic red blood cell (RBC) exchange transfusion and simple transfusion (RCE/T) to prevent complications of disease, such as stroke. These treatment procedures are performed with a target hemoglobin S (HbS) of ≤30%, or a goal of maintaining an HbS level of <30% immediately prior to the next transfusion. However, there is a lack of evidence-based instructions for how to perform RCE/T in a way that will result in an HbS value <30% between treatments. To determine whether targets for post-treatment HbS (post-HbS) or post-treatment HCT (post-HCT) can help to maintain an HbS <30% or <40% between treatments. We performed a retrospective study of patients with SCD treated with RCE/T at Montefiore Medical Center from June 2014 to June 2016. The analysis included patients of all ages, and data including 3 documented parameters for each RCE/T event: post-HbS, post-HCT, and follow-up HbS (F/u-HbS), which is the pre-treatment HbS prior to the next RCE/T. Generalized linear mixed model was used for estimating the association between post-HbS or post-HCT levels and F/u-HbS <30%. Based on our results, targeting post-HbS ≤10% was associated with higher odds of having events of F/u-HbS <30% between monthly treatments. Targeting post-HbS ≤15% was associated with higher odds of events of F/u-HbS < 40%. As compared to post-HCT ≤30%, a post-HCT >30%-36% did not contribute to more F/u-HbS <30% or HbS <40% events. For patients with SCD undergoing regular RCE/T for stroke prevention, a post-HbS ≤10% can be used as a goal to help maintain an HbS <30% for 1 month, and a post-HbS ≤15% allowed patients to maintain HbS <40%.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with sickle cell disease (SCD) frequently undergo prophylactic red blood cell (RBC) exchange transfusion and simple transfusion (RCE/T) to prevent complications of disease, such as stroke. These treatment procedures are performed with a target hemoglobin S (HbS) of ≤30%, or a goal of maintaining an HbS level of <30% immediately prior to the next transfusion. However, there is a lack of evidence-based instructions for how to perform RCE/T in a way that will result in an HbS value <30% between treatments.
PRINCIPAL OBJECTIVE
UNASSIGNED
To determine whether targets for post-treatment HbS (post-HbS) or post-treatment HCT (post-HCT) can help to maintain an HbS <30% or <40% between treatments.
MATERIALS AND METHODS
METHODS
We performed a retrospective study of patients with SCD treated with RCE/T at Montefiore Medical Center from June 2014 to June 2016. The analysis included patients of all ages, and data including 3 documented parameters for each RCE/T event: post-HbS, post-HCT, and follow-up HbS (F/u-HbS), which is the pre-treatment HbS prior to the next RCE/T. Generalized linear mixed model was used for estimating the association between post-HbS or post-HCT levels and F/u-HbS <30%.
RESULTS
RESULTS
Based on our results, targeting post-HbS ≤10% was associated with higher odds of having events of F/u-HbS <30% between monthly treatments. Targeting post-HbS ≤15% was associated with higher odds of events of F/u-HbS < 40%. As compared to post-HCT ≤30%, a post-HCT >30%-36% did not contribute to more F/u-HbS <30% or HbS <40% events.
CONCLUSIONS
CONCLUSIONS
For patients with SCD undergoing regular RCE/T for stroke prevention, a post-HbS ≤10% can be used as a goal to help maintain an HbS <30% for 1 month, and a post-HbS ≤15% allowed patients to maintain HbS <40%.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-539Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Piel FB, Steinberg MH, Rees DC. Sickle cell disease. NEJM. 2017;376(16):1561-1573. doi:10.1056/NEJMra1510865
Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016;128(10):1436-1448.
Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev. 2007 Apr;21(2):118-133. doi:10.1016/j.tmrv.2006.11.003
Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3):772-779. doi:10.1182/blood-2010-01-261123
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294. PMID: 9414296.
DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. NEJM. 2014;317:699-710. doi:10.1035/NEJMoa140731
DeBaun MR, Jordan LC, Kink AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142
US Department of Health and Human Services, National Heart, Lung and Blood Institute. Evidence-Based Management of Sickle Cell Disease, Expert Panel Report, 2014.
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033-1048. doi:10.1001/jama.2014.10517
Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the writing Committee of the American Society of apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171-354. doi:10.1002/jca.21705
Biller E, Zhao Y, Berg M, et al. Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB. Transfusion. 2018;58(8):1965-1972. doi:10.1111/trf.14806
Davis BA, Allard S, Qureshi A, et al. Guidelines on red cell transfusion in sickle cell disease. Part I. principles and laboratory aspects. BJH. 2017;176:179-191. doi:10.1111/bjh.14346
Davis BA, Allard S, Qureshi A, et al. Guidelines on red cell transfusion in sickle cell disease. Part II: indications for transfusion. BJH. 2017;176:192-209. doi:10.1111/bjh.14383
Brown VA. An introduction to linear mixed-effects modeling in R. Adv Methods Pract Psychol Sci. 2021;4(1):1-19. doi:10.1177/2515245920960351
Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood. 2009;114(25):5117-5125. doi:10.1182/blood-2009-05-220921
Pegelow CH. Stroke in children with sickle cell anaemia: aetiology and treatment. Paediatr Drugs. 2001;3(6):421-432. doi:10.2165/00128072-200103060-00003
Lee MT, Piomelli S, Granger S, et al. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood. 2006;108(3):847-852. doi:10.1182/blood-2005-10-009506
Kwiatkowski JL, Voeks JH, Kanter J, et al. Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. Am J Hematol. 2019;94:1335-1343. doi:10.1002/ajh.25635
Himchak E, Friedmann R, Himchak S, et al. Optimizing HbS percentage for pediatric sickle cell disease patients. Adv Cytol Pathol. 2018;3(4):68-72.
Ham TH, Castle WB. Relation of increased hypotonic fragility and of erythrostasis to the mechanism of hemolysis in certain anemias. Trans Assoc Am Physicians. 1940;55:127-132.
Schmalzer EA, Lee JO, Brown AK, Usami S, Chien S. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion. 1987;27(3):228-233. doi:10.1046/j.1537-2995.1987.27387235626.x
Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81(5):1109-1123.
Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood. 1992;79:1657-1661.
Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617-1621. doi:10.1056/NEJM199006073222301
Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med. 1988;148:2485.